Amarantus Bioscience Holdings Inc (AMBS)

[Skeetz99]

MANF in Parkinson’s Disease (per the 10-K)

Our competitors include biotechnology companies focusing on neurotrophic factores for PD such as:


1. MedGenesis is developing GDNF as a disease modifying protein therapy treatment for Parkinson’s disease. This program is currently in a Phase 2 clinical trial using the Renishaw delivery device.


2. Sangamo recently acquired intellectual property rights to Neurturin gene therapy treatment for Parkinson’s disease from Ceregene, Inc. The program recently failed a Phase 2 clinical trial.


3. Hermo Pharma is developing CDNF as a disease modifying protein therapy treatment for Parkinson’s disease. The program is currently in preclinical development.


4. Amsterdam Molecular Therapeutics is developing as a disease modifying gene therapy treatment for Parkinson’s disease. They are currently in preclinical development.


5. Neurodyn is currently developing PDGF as a disease modifying protein therapy treatment for Parkinson’s disease.


6. Academic institutions, governmental agencies and other public and private research organizations are also conducting research activities and seeking patent protection and may commercialize products on their own or through joint ventures. Several of these organizations are currently conducting physician sponsored preclinical and early clinical studies of neurotrophic factor gene therapy and protein therapy applications for Parkinson’s disease.